/PRNewswire-FirstCall/ -- Genitope Corporation
(Nasdaq: GTOP) today announced the appointment of Mary Rybak
, M.D., as the company's vice president of medical affairs.Dr. Rybak
will be responsible for working with Genitope's
executive team to establish and execute the company's long-term clinical strategy for MyVax(R) personalized immunotherapy and other therapies in the company's research and development pipeline.In this role, Dr. Rybak
will be responsible for overseeing clinical research, the implementation of clinical trials, the interpretation of the results of investigations and medical information programs.
"I'm excited by the promise of MyVax(R) personalized immunotherapy, and impressed by the data that has been produced with this therapy.MyVax(R) personalized immunotherapy has tremendous potential to benefit patients and I look forward to exploring all clinical options to integrate it into treatment protocols for follicular Non-Hodgkin's Lymphoma and related cancers," said Dr. Rybak
. "I am also eager to move forward with prospects in the pipeline, such as the promising monoclonal antibody program.It's a great time to be at Genitope
, and I'm thrilled to join the team."Dr. Rybak
has more than 15 years of management and leadership experience in the pharmaceutical industry.Prior to joining Genitope Corporation, Dr. Rybakwas vice president of oncology at Johnson & Johnson Pharmaceutical Research and Development (Johnson & Johnson PRD; formerly Janssen Research Foundation), where she oversaw the initial development of the company's therapeutic oncology unit.She has extensive experience in oncology clinical trial management and led the team that submitted Johnson & Johnson PRD's first NDA for an internally discovered new chemical entity.
Previously, Dr. Rybak
held various research and management positions at Schering Plough Research Institute
(Union, New Jersey), and a number of academic and administrative positions at University of Massachusetts Medical School
.Dr. Rybakearned her doctor of medicine degree from Harvard Medical School and conducted her internship and residency at Brigham and Women's Hospital in Boston, Massachusetts.
"We welcome Dr. Rybak
brings a wealth of experience in all aspects of oncology drug development, including preclinical research, clinical trial design and FDA filings to commercialization and partnering.